It is possible to declare that all these studies suggest the existence of anti-inflammatory properties of SGLT2 inhibitors within the kidney and the heart, thus mediating, in patients affected by T2D, improvements in CV and kidney disease. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.